Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy

Atsutaka Minagawa, Toshiaki Yoshikawa, Masaki Yasukawa, Akitsu Hotta, Mihoko Kunitomo, Shoichi Iriguchi, Maiko Takiguchi, Yoshiaki Kassai, Eri Imai, Yutaka Yasui, Yohei Kawai, Rong Zhang, Yasushi Uemura, Hiroyuki Miyoshi, Mahito Nakanishi, Akira Watanabe, Akira Hayashi, Kei Kawana, Tomoyuki Fujii, Tetsuya NakatsuraShin Kaneko

Research output: Contribution to journalArticlepeer-review

107 Citations (Scopus)

Abstract

Kaneko et al. describe the effective generation of antigen-specific T cell receptor-stabilized CD8αβ T cells from T cell-derived or monocyte-derived iPSCs, both with genetic modification at the iPSC stage. Those T cells showed monoclonal expression of desired TCR and effectively inhibited tumor growth in xenograft cancer models.

Original languageEnglish
Pages (from-to)850-858.e4
JournalCell stem cell
Volume23
Issue number6
DOIs
Publication statusPublished - 2018 Dec 6
Externally publishedYes

Keywords

  • CD8 T cell
  • HLA matched iPS cell
  • T cell differentiation
  • T cell-derived iPS cell
  • TCR gene therapy
  • TCR rearrangement
  • antigen-specific T cell regeneration
  • cancer immunotherapy
  • cytotoxic T cell
  • iPS cell bank

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Cell Biology

Fingerprint

Dive into the research topics of 'Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy'. Together they form a unique fingerprint.

Cite this